Ambry Genetics, a wholly owned subsidiary of Tempus AI (NASDAQ:TEM), has introduced GenomeNext and GenomeReveal, a new whole genome sequencing solution designed to improve the identification of ...

ALISO VIEJO, Calif., February 02, 2026--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the ...

New offering combines whole genome sequencing, RNA analysis and ongoing reanalysis to help address diagnostic challenges Ambry Genetics, a leader in clinical genomic testing and a wholly owned ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., unveiled at the American Society of Human Genetics (ASHG) ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus, a leader in artificial intelligence and precision medicine, announced today that they ...

Shares of Tempus AI TEM gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million. This acquisition will likely help Tempus revolutionize healthcare by ...

Study finds significantly lower rates of provider-initiated exome reanalysis among diverse racial, ethnic, and ancestral groups highlighting the importance of proactive reanalysis offerings like Ambry ...

Add Yahoo as a preferred source to see more of our stories on Google. Medical research testing ©Hagerty Ryan, USFWS Ambry Genetics, a wholly owned subsidiary of Tempus AI (NASDAQ:TEM), has introduced ...

GenomeNext analyzes a patient's genome using a pangenome reference designed to better represent human genetic diversity and improve variant detection across diverse ancestral backgrounds, alongside ...